supplemental material for peer review：<b>Efficacy and Safety of Incretin-based Therapies in Patients with Metabolic-Dysfunction Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.</b>
Creators: name: Zhang, Yiyu
Publisher: name: figshare
Year: 2024
Subjects: classificationCode: 320208
subject: Endocrinology

description: <b>Efficacy and Safety of Incretin-based Therapies in Patients with Metabolic-Dysfunction Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.</b><br><b>Authors</b>: Lili Liu<sup>1</sup>, Bian Wang<sup>2</sup>, Yiyu Zhang<sup>2*</sup><br><b>Affiliations:</b><sup>1</sup>National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, Metabolic Syndrome Research Center, and Department of Metabolism and Endocrinology, the Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan, China<sup>2</sup>Department of Endocrinology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410000 Hunan, China<br><b>*Correspondence author: </b>Yiyu Zhang, Ph.D.E-mail address: 2020050003@usc.edu.cnORCID: 0000-0003-3201-0468<br><br><b>Supplemental material</b>1. Supplemental appendix 1: Search Strategies of the Major Databases.2. Supplementary Figure 1 funnel plots. A, liver fat content (LFC); B, alanine aminotransferase (ALT); C, aspartate aminotransferase (AST); D, body weight; E, body mass index (BMI); F, waist circumstance (WC); G, glycosylated hemoglobin (HbA1c); H, triglyceride (TG); I, total cholesterol (TC); J, low density lipoprotein cholesterol (LDL-C); K, high density lipoprotein cholesterol (HDL-C).<br><b>Supplemental appendix 1: Search Strategies of the Major Databases</b>Search date: June 6, 2024Search strategy for PubMed1104#1 “Non-alcoholic Fatty Liver Disease” OR “NAFLD” OR “Metabolic associated fatty liver disease” OR “MAFLD” OR “Metabolic-dysfunction associated fatty liver disease” OR “Metabolic-dysfunction associated steatotic liver disease” OR “MASLD” OR “Nonalcoholic Fatty Liver Disease” OR “Fatty Liver” OR “Nonalcoholic Fatty Liver” OR “Nonalcoholic Steatohepatitis” OR “Non-alcoholic Steatohepatitis” OR “NASH” OR “Metabolic dysfunction-associated Steatohepatitis” OR “MASH”#2 “glucagon like peptide 1 receptor agonist” OR “glucagon-like peptide 1 agonist” OR “GLP-1 receptor agonist” OR “GLP-1 agonist” OR “GLP-1” OR “glucagon like peptide 1” OR “exenatide” OR “liraglutide” OR “benaglutide” OR “beinaglutide” OR “lixisenatide” OR “dulaglutide” OR “loxenatide” OR “PEX168” OR “efinopegdutide” OR “semaglutide” OR “tirzepatide” OR “DPP4 inhibitor” OR “DPP-4 inhibitor” OR “Vildagliptin” OR “LAF237” OR “Sitagliptin” OR “MK-0431” OR “Linagliptin” OR “BI1356” OR “Alogliptin” OR “SYR-322” OR “Saxagliptin” OR “BMS-477118” OR “Gemigliptin” OR “LC15-0444” OR “Dutogliptin” OR “PHX1149” OR “Gosogliptin” OR “PF-734200” OR “HM15211”#3 #1 AND #2<br>Search strategy for the Cochrane Library980#1 Non-alcoholic Fatty Liver Disease OR NAFLD OR Metabolic associated fatty liver disease OR MAFLD OR Metabolic-dysfunction associated fatty liver disease OR Metabolic-dysfunction associated steatotic liver disease OR MASLD OR Nonalcoholic Fatty Liver Disease OR Fatty Liver OR Nonalcoholic Fatty Liver OR Nonalcoholic Steatohepatitis OR Non-alcoholic Steatohepatitis OR NASH OR Metabolic dysfunction-associated Steatohepatitis OR MASH#2 glucagon like peptide 1 receptor agonist OR glucagon-like peptide 1 agonist OR GLP-1 receptor agonist OR GLP-1 agonist OR GLP-1 OR glucagon like peptide 1 OR exenatide OR liraglutide OR benaglutide OR beinaglutide OR lixisenatide OR dulaglutide OR loxenatide OR efinopegdutide OR semaglutide OR tirzepatide OR Dipeptidyl Peptidase IV Inhibitor OR DPP4 inhibitor OR DPP-4 inhibitor OR Vildagliptin OR Sitagliptin OR Linagliptin OR Alogliptin OR Saxagliptin OR Gemigliptin OR Dutogliptin OR Gosogliptin OR PF-734200 OR HM15211 OR PEX168 OR BI1356 OR LAF237 OR SYR-322 OR BMS-477118 OR PHX1149 OR MK-0431#3 #1 AND #2<br>Search strategy for Embase1787#1 'non-alcoholic fatty liver disease':ab,ti OR nafld:ab,ti OR 'metabolic associated fatty liver disease':ab,ti OR mafld:ab,ti OR 'metabolic-dysfunction associated fatty liver disease':ab,ti OR 'metabolic-dysfunction associated steatotic liver disease':ab,ti OR masld:ab,ti OR 'nonalcoholic fatty liver disease':ab,ti OR 'fatty liver':ab,ti OR 'nonalcoholic fatty liver':ab,ti OR 'nonalcoholic steatohepatitis':ab,ti OR 'non-alcoholic steatohepatitis':ab,ti OR nash:ab,ti OR 'metabolic dysfunction-associated steatohepatitis':ab,ti OR mash:ab,ti#2 'glucagon like peptide 1 receptor agonist':ab,ti OR 'glucagon-like peptide 1 agonist':ab,ti OR 'glp-1 receptor agonist':ab,ti OR 'glp-1 agonist':ab,ti OR 'glp 1':ab,ti OR 'glucagon like peptide 1':ab,ti OR exenatide:ab,ti OR liraglutide:ab,ti OR benaglutide:ab,ti OR beinaglutide:ab,ti OR lixisenatide:ab,ti OR dulaglutide:ab,ti OR loxenatide:ab,ti OR efinopegdutide:ab,ti OR semaglutide:ab,ti OR tirzepatide:ab,ti OR 'dipeptidyl peptidase iv inhibitor':ab,ti OR 'dpp4 inhibitor':ab,ti OR 'dpp-4 inhibitor':ab,ti OR vildagliptin:ab,ti OR sitagliptin:ab,ti OR linagliptin:ab,ti OR alogliptin:ab,ti OR saxagliptin:ab,ti OR gemigliptin:ab,ti OR dutogliptin:ab,ti OR gosogliptin:ab,ti OR 'pf 734200':ab,ti OR hm15211:ab,ti OR pex168:ab,ti OR bi1356:ab,ti OR laf237:ab,ti OR 'syr 322':ab,ti OR 'bms 477118':ab,ti OR phx1149:ab,ti OR 'mk 0431':ab,ti#3 #1 AND #2<br><br><br><br>